News

ViraDx™ Receives Interim Order Authorization from Health Canada

June 28, 2022

Lumos Diagnostics Introduces 15-minute ViraDx™ Test for COVID-19, Flu A and Flu B.

READ MORE
June 21, 2022

Lumos Diagnostics Appoints Doug Ward As CEO

Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance.

READ MORE
November 3, 2021

Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Test in Canada

MELBOURNE, VIC. (03 November 2021): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted Interim Order authorization for the Lumos CoviDx™ SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified … Continued

READ MORE
October 24, 2021

Box Hill Hospital Emergency Department Initiates Trial Using FebriDx®

MELBOURNE, VIC. (24 October 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® … Continued

READ MORE
October 6, 2021

Economic Evaluation of Lumos Diagnostics’ FebriDx® Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

SARASOTA, Fla. (October 6, 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Journal of Health Economics and Outcomes Research (JHEOR) has published an economic study that concludes using the FebriDx® … Continued

READ MORE
September 13, 2021

Dr. Jerome Adams, Former U.S. Surgeon General, Joins Lumos Diagnostics as a Strategic Healthcare Adviser

Immediate former U.S. Surgeon General, Jerome Adams, MD, MPH, will join Lumos as a Strategic Healthcare Adviser and will be appointed to the Company’s Medical Advisory Board.

READ MORE
August 30, 2021

Lumos Diagnostics FY21 Full Year Results

Lumos announced its FY21 full year results including Appendix 4E and Annual Report to Shareholders for the fiscal year ending on 30 June 2021.

READ MORE

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.